Abstract 19941: Clinical and Demographic Characteristics According to Dosage Among New Initiators and/or Switchers From Warfarin Non-valvular Atrial Fibrillation Patients on Apixaban, Dabigatran and Rivaroxaban
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia [1-3] with increasing prevalence in the aging . With the advent of the three NOACs including apixaban, dabigatran and rivaroxaban, it is important to characterize patients prescribed with the different dosage of treatment in the real-world setting.
Purpose: To describe the baseline clinical and demographic characteristics of NVAF patients on apixaban (5 mg vs 2.5 mg -reduced), rivaroxaban (20mg vs reduced dose: 15 mg or 10 mg), and dabigatran (150 mg vs reduced 75 mg).
Methods: A retrospective cohort study was conducted using MarketScan Earlyview® data. NVAF patients ≥18 years with a minimum of 1 year baseline period were included if they either received a NOAC or were switched from warfarin to NOAC during the study period of Jan 1, 2013 to October 31, 2014.
Results: For NVAF patients , the majority of the patients were on the standard dosage (Table 1). Similarly for each NOAC, patients using low dosage versus standard dosage were older, had a greater stroke risk, had a prior history of bleeding and were sicker in terms of presence of congestive heart disease, renal disease and Charleson comorbidity index. Patients switching from warfarin had on average a large number of missing dosage data, and if switching to apixaban were more likely to be prescribed the reduced dose than the 5 mg dose. No clear trend was observed for patients switching to dabigatran or rivaroxaban. More than 15% Apixaban and rivaroxaban patients switched from warfarin while only <6% dabigatran patients switched from warfarin.
Conclusion: AF patient initiated with standard dosages of NOACs had better clinical and demographic characteristics than patients initiated with reduced dosages of NOAC.
Author Disclosures: P. Tepper: Research Grant; Significant; Recieved research grant from Pfizer. C. Masseria: Employment; Significant; Pfizer. Ownership Interest; Significant; Stocks at Pfizer. J. Mardekian: Employment; Significant; Pfizer. Ownership Interest; Significant; Stocks at Pfizer. P. Hemant: Employment; Significant; Bristol Myers Squibb. Ownership Interest; Significant; Stocks at Bristol Myers Squibb. S. Kamble: Employment; Significant; Bristol Myers Squibb. Ownership Interest; Significant; Stocks at Bristol Myers Squibb. Y. Ravee: Employment; Significant; Pfizer. Y. Abdulsattar: Employment; Significant; Pfizer. Ownership Interest; Significant; Stocks at Pfizer. W. Petkun: Employment; Significant; Bristol Myers Squibb. Ownership Interest; Significant; Stocks at Bristol Myers Squibb. G. Lip: Consultant/Advisory Board; Significant; Consultant-Bayer, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Medtronic, Portola and Boehringer Ingelheim. Speakers bureau- Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic.
- © 2015 by American Heart Association, Inc.